European Journal of Heart Failure

Papers
(The H4-Index of European Journal of Heart Failure is 56. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)
ArticleCitations
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure1093
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Soci750
Self‐care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology231
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial211
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and208
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial 197
Heart failure in COVID‐19 patients: prevalence, incidence and prognostic implications182
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology182
The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019158
Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy123
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study119
Ultrasound imaging of congestion in heart failure: examinations beyond the heart112
Primary results of long‐term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implan110
Circulating cardiovascular microRNAs in critically ill COVID‐19 patients107
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)106
Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care106
Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper105
Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) 104
Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure104
Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction103
Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID‐19. Results of the Cardio‐COVID‐Italy multicentre study103
A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT‐HF100
Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta‐analysis97
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure92
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial92
Cachexia, muscle wasting, and frailty in cardiovascular disease88
Association of COVID‐19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection85
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies83
Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC83
Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction82
Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy81
Trial characteristics associated with under‐enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review81
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction81
Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review80
Myocarditis following COVID‐19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart79
Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction79
Haemodynamic characteristics of COVID‐19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization78
Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction76
Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta‐regression in the past four decades76
The cancer patient and cardiology75
A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction – insights from the ESC‐HFA EORP Heart Failure Long‐Term Regist74
Characterization of NT‐proBNP in a large cohort of COVID‐19 patients73
Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology71
Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology70
Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subje70
Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial69
Ejection fraction and mortality: a nationwide register‐based cohort study of 499 153 women and men69
Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy – A clinical consensus statement of the Heart Failure Association and Eu68
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics68
Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy68
Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients – a prospective cohort study67
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure66
Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure65
Effect of dapagliflozin on anaemia in DAPA‐HF64
A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF‐HFpEF61
Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology61
OUTSTEP‐HF: randomised controlled trial comparing short‐term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fr56
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC‐TIVE study, an Italian nationwide survey56
0.024461030960083